Matching articles for "Afrezza"
Insulins for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 6, 2019; (Issue 1571)
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is...
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is <7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control.
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • May 6, 2019; (Issue 1571)
...
View the Expanded Table: Some Available Insulins
Fiasp - Another Insulin Aspart Formulation for Diabetes
The Medical Letter on Drugs and Therapeutics • January 1, 2018; (Issue 1537)
The FDA has approved Fiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes. Fiasp is described by
the manufacturer as faster-acting than...
The FDA has approved Fiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes. Fiasp is described by
the manufacturer as faster-acting than conventional
insulin aspart (Novolog).
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 16, 2017; (Issue 1512)
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating...
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating to this target has been shown to
prevent microvascular complications (retinopathy,
nephropathy, and neuropathy), but whether it prevents
macrovascular outcomes is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease, a history of
severe hypoglycemia, diabetes-related complications
or comorbidities, or a long duration of disease.
An Inhaled Insulin (Afrezza)
The Medical Letter on Drugs and Therapeutics • March 2, 2015; (Issue 1463)
The FDA has approved an inhaled, rapid-acting, dry-powder
formulation of recombinant human insulin
(Afrezza – Mannkind/Sanofi) for treatment of adults
with type 1 or type 2 diabetes. In patients with type...
The FDA has approved an inhaled, rapid-acting, dry-powder
formulation of recombinant human insulin
(Afrezza – Mannkind/Sanofi) for treatment of adults
with type 1 or type 2 diabetes. In patients with type 1
diabetes, the drug must be used in combination with
long-acting insulin. Another inhaled, rapid-acting
insulin (Exubera) was approved in 2006 for the same
indication, but was withdrawn from the market the
following year.